Featured Research

from universities, journals, and other organizations

New understanding of why anti-cancer therapy stops working at a specific stage

Date:
June 24, 2013
Source:
The Hebrew University of Jerusalem
Summary:
Researchers have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells. Their work could lead to new insights into overcoming this impasse.

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells. Their work could lead to new insights into overcoming this impasse.

The problematic therapy investigated involves suppression of the protein mTOR (mammalian target Of Rapamycin). MTOR plays an important role in regulating how cells process molecular signals from their environment, and it is observed as strongly activated in many solid cancers.

Drug-induced suppression of mTOR has until now shown success in causing the death of cancer cells in the outer layers of cancerous tumors, but has been disappointing in clinical trials in dealing with the core of those tumors.

Reduced oxygen supply -- hypoxia -- is a near-universal feature of solid tumors that can alter how tumors respond to therapies. It was known that the behavior of mTOR signaling is influenced and altered by the condition of hypoxia, but the mechanism to explain this was unknown.

A research team, which included Prof. Emeritus Raphael D. Levine of the Institute of Chemistry at the Hebrew University of Jerusalem and researchers from the California Institute of Technology and the David Geffen School of Medicine at UCLA, investigated whether the influence of hypoxia on mTOR signaling in model brain cancer systems could explain the poor performance of mTOR drugs. Their work appeared in a recent article in the Proceedings of the National Academy of Sciences (PNAS) in the US.

For their investigation, they employed a new microchip technology that allowed them to measure the mTOR protein signaling network in individual cancer cells, and they interpreted the results using a new set of theoretical tools derived from the physical sciences. The combined approach permitted the simplification of an otherwise complex biological system.

They found that at a particular level of oxygen starvation (hypoxia) that is common in solid tumors, the mTOR signaling network switches between two sets of properties. At the switching point, the theoretical models predicted that mTOR would be intrinsically unresponsive to drugging.

Furthermore, the combined experiment and theory results indicated that the switch could be interpreted as a type of phase transition, which has not been previously observed in biological systems.

This phase transition is the point of the switch between the two signaling networks and happens very abruptly. The change in signaling means that the body of cells studied no longer responds in the way it did before. In the case of the tumor, the "drugging" of the mTOR ceases, meaning that the tumor is no longer inhibited.

These results have several implications. First, they may explain the poor clinical performance of mTOR inhibitors. Second, they indicate that certain complex biological behaviors, which often confound scientists who are seeking to find effective therapies for human diseases, may be understood by the effective application of experimental and theoretical tools derived from the physical sciences.


Story Source:

The above story is based on materials provided by The Hebrew University of Jerusalem. Note: Materials may be edited for content and length.


Journal Reference:

  1. W. Wei, Q. Shi, F. Remacle, L. Qin, D. B. Shackelford, Y. S. Shin, P. S. Mischel, R. D. Levine, J. R. Heath. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proceedings of the National Academy of Sciences, 2013; 110 (15): E1352 DOI: 10.1073/pnas.1303060110

Cite This Page:

The Hebrew University of Jerusalem. "New understanding of why anti-cancer therapy stops working at a specific stage." ScienceDaily. ScienceDaily, 24 June 2013. <www.sciencedaily.com/releases/2013/06/130624093522.htm>.
The Hebrew University of Jerusalem. (2013, June 24). New understanding of why anti-cancer therapy stops working at a specific stage. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/06/130624093522.htm
The Hebrew University of Jerusalem. "New understanding of why anti-cancer therapy stops working at a specific stage." ScienceDaily. www.sciencedaily.com/releases/2013/06/130624093522.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins